Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction.
Song. Kibbeum K; Han. Hye-Ju HJ; Kim. Sokho S; Kwon. Jungkee J
Key Findings
- Thymosin beta‑4 increased levels of tight‑junction proteins in human brain endothelial cells.
- It lowered the ratio of filamentous (F‑actin) to globular (G‑actin), indicating a more stable cytoskeleton.
- Treatment with thymosin beta‑4 reduced the increased permeability caused by the prion peptide PrP(106‑126).
Practical Outcomes
- For biohackers, this suggests thymosin beta‑4 might support BBB health and offer neuroprotective benefits, especially in contexts of neuro‑inflammation or protein‑misfolding stress. However, the evidence is limited to cell‑culture experiments, so no specific dosing or protocol can be recommended yet. It may be worth monitoring future animal or human studies before incorporating it for brain‑barrier support.
Summary
The study shows that the peptide thymosin beta‑4 can help keep the brain's blood‑brain barrier (BBB) intact when it’s damaged by a prion‑related protein, at least in human brain‑cell cultures. It does this by boosting tight‑junction proteins and changing the actin skeleton inside the cells, which together reduce leakiness of the barrier.
Abstract
The blood-brain barrier (BBB) is a highly selective permeability barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system (CNS). The BBB is formed by cerebral endothelial cells connected by tight junctions. Prion diseases are neurodegenerative pathologies characterized by the accumulation of altered forms of the prion protein (PrP), named PrP<sup>Sc</sup>. Thymosin beta 4 (Tβ<sub>4</sub>) is an actin-sequestering peptide known to bind monomeric actin and inhibit its polymerization, and it is known to have a neuroprotective effect. However, the effect of Tβ<sub>4</sub> on prion disease has not yet been investigated. Therefore, in this study, we investigated the effect of Tβ<sub>4</sub> on prion-induced BBB dysfunction in hCMEC/D3 human cerebral endothelial cells. We found that Tβ<sub>4</sub> increased the expression of tight junction protein, but reduced the ratio of F-actin to G-actin. Moreover, we showed that Tβ<sub>4</sub> significantly improved PrP (106-126)-induced vascular permeability dysfunction in hCMEC/D3 cells. Through human BBB in vitro model, we found that PrP (106-126) could disrupt tight junctions and cytoskeleton arrangement. These results suggest that Tβ<sub>4</sub> may play a critical role in barrier stabilization. Furthermore, Tβ<sub>4</sub> may prevent neurodegenerative diseases caused by prion-induced BBB dysfunction.
Study Information
pubmed
2019
2019-12-23T00:00:00.000Z
10.1016/j.ejphar.2019.172891
9
53